{
  "docId": "019de074-2973-7208-9395-338d3116556a",
  "docSlug": "4059563425860536cb0bf09c6eb6bba5",
  "documentTitle": "BenevolentAI | Investor Conference Presentation Deck | 29 slides",
  "authorId": "benevolentai",
  "authorName": "BenevolentAI",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 19,
  "pageCount": 29,
  "prevPage": 18,
  "nextPage": 20,
  "slideType": "problem_statement",
  "function": "frame_problem",
  "density": "dense",
  "nDataPoints": 4,
  "notes": "The slide uses a two-column layout to contrast the disease burden (left) with the proposed therapeutic solution (right).",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-2973-7208-9395-338d3116556a/19",
  "deckHref": "/decks/019de074-2973-7208-9395-338d3116556a",
  "deckJsonHref": "/decks/019de074-2973-7208-9395-338d3116556a.json",
  "deckAnchorHref": "/decks/019de074-2973-7208-9395-338d3116556a#slide-19",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.48,
        "x": 0.48,
        "y": 0.06
      },
      "kind": "callout",
      "text": "Topical best-in-class PanTrk inhibitor to relieve inflammation and rapidly resolve itch in patients with AD",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7d95a13c-7042-4555-9ee0-755f27d933fd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 1,
        "w": 0.4,
        "x": 0.6,
        "y": 0
      },
      "kind": "image",
      "text": null,
      "attrs": null,
      "subkind": "photo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0efb4fd3-dc35-4efe-b0a8-44f39ab15afe",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.4,
        "x": 0.05,
        "y": 0.25
      },
      "kind": "list",
      "text": "Atopic dermatitis is the most common chronic inflammatory skin disease... Affects 10-20% of children... 60-70% of cases mild-moderate... market value >$14 billion",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0f73d7d0-b713-4d25-8b88-1e687f1dfc42",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.45,
        "x": 0.43,
        "y": 0.25
      },
      "kind": "list",
      "text": "BEN-2293 is a PanTrk inhibitor... treat atopic dermatitis by inhibiting itch signaling... target Mild, Moderate and Severe Atopic Dermatitis patients",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9c04aa89-78aa-4712-a76f-21b5b95d45da",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.05,
        "y": 0.93
      },
      "kind": "source-note",
      "text": "Sources: (1) Weidinger et al. Nat Rev Dis Primers 2018; (2) GlobalData Report 2018: Atopic Dermatitis: Global Drug Forecast and Market Analysis to 2027; (3) GlobalData Report 2018: Atopic Dermatitis: Epidemiology Forecast to 2027; (4) Evaluate Pharma",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c91da7e3-1438-413c-b53e-9e0f9912024d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.4,
        "x": 0.05,
        "y": 0.09
      },
      "kind": "title",
      "text": "BEN-2293 Atopic Dermatitis (AD)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a8b317aa-cea2-4d74-a782-f645e9c5475d",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Problem Statement Canvas",
      "slug": "problem-statement-canvas",
      "agent": "Architect",
      "layer": "slide",
      "matchId": "37ef4872-965b-4618-9a9a-69976a177cee",
      "evidence": "The slide's content, including the description of atopic dermatitis and the need for a treatment, resembles a problem statement canvas used to define a problem and its context.",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 29,
      "from": 16,
      "beatId": "3b0e5288-2029-43c9-ada8-d64afac944d7",
      "arcName": "The Sparkline",
      "arcSlug": "sparkline",
      "beatName": "Action",
      "beatSlug": "aida-action",
      "evidence": "The call to action is clear, with a roadmap and ask for investors",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 20,
      "from": 19,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "b2de1916-1b79-40d9-9966-3475d4152b9a",
      "evidence": "The presentation highlights the limitations of current treatments",
      "position": 0,
      "objective": "Highlight the need for new treatments",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}